cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25549/examiner-c44-55255
title: Los Angeles City Police Crime Laboratory feature, 1955

description: 12 images. Los Angeles City Police Crime Laboratory feature, 13 April 1955. Ray Pinker (Chief Criminalist); William Penprase (Police chemist); Sergeant Jay Allen; Sergeant Daniel McCauley; Dewayne Wolfer (Firearms expert); Warren M. Stilson; Officer Lee Jones.; Caption slip reads: "Photographer: Gray. Date: 04-13. Reporter: Adler. Assignment: Crime Lab. Monday. 8: Firearms Identification Expert Dewayne Wolfer examining fired cartridge case in comparison microscope, while Capt. Warren M. Stilson, commander of LAPD's Scientific Investigation Division, examines gun. 2/3/4/, l to r: Capt. Warren M. Stilson; Lt. Lee Jones, assist commander of Scientific Investigation Division, and Chief Criminalist Ray Pinker in Pinker's new office and laboratory in the new Police Building. 23, front to back: Lt. Lee Jones; Ray Pinker and Capt. Warren Stilson in new building's negative file room. 27/28: Chief Criminalist Ray Pinker at his overloaded desk in the present Crime Lab in the old Central Jail. 37/38: Chief Criminalist Ray Pinker at his desk in present quarters, with Police Chemist William Penprase working on a titration in the background -- note crammed office--laboratory. 25/26, l to r: Sgt. Jay Allen examining spectographic film while Sgt. Daniel McCauley makes a spectographic analysis in tiny present quarters. 7: Firearms Identification Expert Dewayne Wolfer examining fired cartridge cases in a comparison microscope. 24: Shots looking along hallway on fourth floor of new Police Building, the floor occupied by LAPD's Scientific Investigation Division".
DOI: 10.25402/fon.17026349.v1
title: Supplementary Material 1 - Low expression of Trefoil factor 3 in papillary thyroid carcinoma may correlate with poor prognoses but high immune cell infiltration

description: Supplementary Information 1: Low expression of Trefoil factor 3 in papillary thyroid carcinoma may correlate with poor prognoses but high immune cell infiltration <br>Gene symbol transformation annotation in DEGs analysis<br>Abstract: <br>Background: Papillary thyroid carcinoma (PTC) is most common endocrine malignancies with favorable prognosis. However, current treatments and prognostic markers have not been clearly identified. <br>Methods: Gene expression data from primary PTC were downloaded from the GEO database and subjected to two analyses of differentially expressed genes (DEGs), followed by intersecting individual and integrated DEGs analyses as well as gene set enrichment analysis. SRA, TCGA database and IHC, qRT-PCR of TFF3 were performed to validate the results. Finally, the relationship between gene expression and disease-free survival as well as immune cell infiltration were investigated. <br>Results: Six critical DEGs and several tumor-enriched signaling pathways were identified. IHC and qRT-PCR validated the low expression of TFF3 in PTC. TFF3 and FCGBP are coexpressed in PTC, and patients with lower gene expression had worse disease-free survival but higher immune cell infiltration. <br>Conclusion: TFF3 was significantly underexpressed and may function with FCGBP synergistically in PTC.
DOI: 10.25402/fon.17026385
title: Supplementary Material 2 - Low expression of Trefoil factor 3 in papillary thyroid carcinoma may correlate with poor prognoses but high immune cell infiltration

description: Supplementary Information 2: Low expression of Trefoil factor 3 in papillary thyroid carcinoma may correlate with poor prognoses but high immune cell infiltration <br>RT-qPCR protocol information following MIQE guidelines <br>Abstract: <br>Background: Papillary thyroid carcinoma (PTC) is most common endocrine malignancies with favorable prognosis. However, current treatments and prognostic markers have not been clearly identified. <br>Methods: Gene expression data from primary PTC were downloaded from the GEO database and subjected to two analyses of differentially expressed genes (DEGs), followed by intersecting individual and integrated DEGs analyses as well as gene set enrichment analysis. SRA, TCGA database and IHC, qRT-PCR of TFF3 were performed to validate the results. Finally, the relationship between gene expression and disease-free survival as well as immune cell infiltration were investigated. <br>Results: Six critical DEGs and several tumor-enriched signaling pathways were identified. IHC and qRT-PCR validated the low expression of TFF3 in PTC. TFF3 and FCGBP are coexpressed in PTC, and patients with lower gene expression had worse disease-free survival but higher immune cell infiltration. <br>Conclusion: TFF3 was significantly underexpressed and may function with FCGBP synergistically in PTC.
DOI: 10.25549/examiner-c44-75249
title: American Legion fireworks at Coliseum, 1955

description: 4 images. American Legion fireworks at Coliseum, 29 June 1955. Camille Williams -- 23 years ("Miss Firecracker"); Harry Myers (Legion Special Events Director); Eugene Howard (truck driver).; Caption slip reads: "Photographer: Miller. Date: 1955-06-29. Reporter: Dunn. Assignment: Legion fireworks show at Coliseum. (L to R) Miss Firecracker, Camille Williams, 23, hands fireworks to Harry Myers, Legion special events director. (L to R) truck driver Eugene Howard and Camille Williams, Miss Firecracker".
DOI: 10.25402/fon.17026385.v3
title: Supplementary Material 2 - Low expression of Trefoil factor 3 in papillary thyroid carcinoma may correlate with poor prognoses but high immune cell infiltration

description: Supplementary Information 2: Low expression of Trefoil factor 3 in papillary thyroid carcinoma may correlate with poor prognoses but high immune cell infiltration <br>RT-qPCR protocol information following MIQE guidelines <br>Abstract: <br>Background: Papillary thyroid carcinoma (PTC) is most common endocrine malignancies with favorable prognosis. However, current treatments and prognostic markers have not been clearly identified. <br>Methods: Gene expression data from primary PTC were downloaded from the GEO database and subjected to two analyses of differentially expressed genes (DEGs), followed by intersecting individual and integrated DEGs analyses as well as gene set enrichment analysis. SRA, TCGA database and IHC, qRT-PCR of TFF3 were performed to validate the results. Finally, the relationship between gene expression and disease-free survival as well as immune cell infiltration were investigated. <br>Results: Six critical DEGs and several tumor-enriched signaling pathways were identified. IHC and qRT-PCR validated the low expression of TFF3 in PTC. TFF3 and FCGBP are coexpressed in PTC, and patients with lower gene expression had worse disease-free survival but higher immune cell infiltration. <br>Conclusion: TFF3 was significantly underexpressed and may function with FCGBP synergistically in PTC.
DOI: 10.25402/fon.17026589
title: Supplementary Table 2 – Patterns of colorectal cancer diagnosis among younger adults in a real-world, population-based cohort

description: Supplementary Table 2. Patterns of colorectal cancer diagnosis among younger adults in a real-world, population-based cohort <br>Percentage of individuals 15-49 years in Alberta within 3 censuses (2006-2011-2016).
DOI: 10.25549/examiner-c44-80033
title: Divorce, 1960

description: 2 images. Divorce, 22 November 1960. Maria Barner - 29 Years.; Caption slip reads: "Photographer: Paegel. Date: 1960-11-22. Reporter: Garner. Assignment: Divorce. Special Instructions: Rollie Negs. 5/6: Maria Barner, 29, please hold for Thursday RX release...."
DOI: 10.25549/examiner-c44-44596
title: Plymire murder preliminary hearing, 1952

description: 2 images. Plymire murder preliminary hearing, 17 April 1952. Mrs. Barbara Joy Plymire (suspect).
DOI: 10.25402/fon.17026769
title: Supplementary Table 1: Impact of ALK fusion variant on clinical outcomes in EML4-ALK NSCLC patients: a systematic review and meta-analysis

description: Supplementary Table 1: Impact of ALK Fusion Variant on Clinical Outcomes in EML4-ALK NSCLC Patients: a systematic review and meta-analysis.Quality assessment of eligible studies using the Newcastle Ottawa quality assessment scale<br>AbstractBackground: Emerging studies showed that ALK-fusion variants were associated with heterogeneous clinical outcomes. However, contradicting conclusions drew in some other studies considered no correlation between ALK variants and prognoses. Methods: we performed a systematic review and meta-analysis to evaluated the prognostic value of EML4-ALK fusion variants for the outcome of patients. Results: 28 studies were included in our analysis. According to the pooled results, patients harboring variant 1 showed equivalent PFS and OS with non-v1 (HR for PFS: 0.91(0.68-1.21), p=0.499; for OS: 1.12(0.73-1.72), p=0.610). Similarly, patients with v3 showed the same disease progress with non-v3 (pooled HR for PFS=1.07(0.72-1.58), p=0.741). However, pooled results for OS suggested that patients with v3 had a worse survival than non-v3 (HR=3.44(1.42-8.35), p=0.006). Conclusion: Overall results suggested that patients with v1 exhibited no significant difference with non-v1 in terms of OS and PFS, while v3 was associated with shorter OS in ALK-positive NSCLC patients.<br><br>
DOI: 10.25402/fon.17026769.v1
title: Supplementary Table 1: Impact of ALK fusion variant on clinical outcomes in EML4-ALK NSCLC patients: a systematic review and meta-analysis

description: Supplementary Table 1: Impact of ALK Fusion Variant on Clinical Outcomes in EML4-ALK NSCLC Patients: a systematic review and meta-analysis.Quality assessment of eligible studies using the Newcastle Ottawa quality assessment scale<br>AbstractBackground: Emerging studies showed that ALK-fusion variants were associated with heterogeneous clinical outcomes. However, contradicting conclusions drew in some other studies considered no correlation between ALK variants and prognoses. Methods: we performed a systematic review and meta-analysis to evaluated the prognostic value of EML4-ALK fusion variants for the outcome of patients. Results: 28 studies were included in our analysis. According to the pooled results, patients harboring variant 1 showed equivalent PFS and OS with non-v1 (HR for PFS: 0.91(0.68-1.21), p=0.499; for OS: 1.12(0.73-1.72), p=0.610). Similarly, patients with v3 showed the same disease progress with non-v3 (pooled HR for PFS=1.07(0.72-1.58), p=0.741). However, pooled results for OS suggested that patients with v3 had a worse survival than non-v3 (HR=3.44(1.42-8.35), p=0.006). Conclusion: Overall results suggested that patients with v1 exhibited no significant difference with non-v1 in terms of OS and PFS, while v3 was associated with shorter OS in ALK-positive NSCLC patients.<br><br>
DOI: 10.25402/fon.17032076
title: Supplementary Material: Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study

description: Supplementary Figure 1. Kaplan-Meier curves for overall survival in patients with NSQ NSCLC by TNM stage and year of diagnosis in Denmark. A) Stage I, B) Stage II, C) Stage IIIA, D) Stage IIIB and E) Stage IV. Data were truncated at month 138.<br>Supplementary Figure 2. Kaplan-Meier curves for overall survival in patients with SQ NSCLC by TNM stage and year of diagnosis in Denmark. A) Stage I, B) Stage II, C) Stage IIIA, D) Stage IIIB and E) Stage IV. Data were truncated at month 138.<br>Supplementary Table 1. ICD-10 morphology codes for NSCLC.<br>Supplementary Table 2. Initial treatment categories and definitions. Initial treatment was defined as the first treatment received within 6 months of diagnosis, associated with any other treatment received within a certain time period following first treatment as defined in the table below<br>Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study<br><br>ABSTRACTAim: Describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use.Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported.Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I&II/IIIA&IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous (53.0-60.6%) but not squamous (44.9-47.3%) NSCLC. One-year OS improved in patients with stage IV non-squamous (23-31%) but not squamous (22-25%) NSCLC. <br>
DOI: 10.25549/examiner-c44-10385
title: "Miss Smog Fighter", 1951

description: 4 images. "Miss Smog Fighter", May 22, 1951. Helene Stanley ("Miss Smog Fighter"); Lee W. Warburton (councilman).; More descriptive information with originals.
DOI: 10.25402/fon.17075384
title: Supplementary Table 1. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer

description: Supplementary Table 1. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer <br>COX regression analysis of Gene mutation types and TKI drug types
DOI: 10.25549/examiner-c44-52520
title: Baseball World Series, fourth game, Los Angeles versus Chicago White Sox, 1959

description: 31 images. Baseball World Series, fourth game, Los Angeles versus Chicago White Sox, 5 October 1959. Carl Furillo; Bob Hunter; Roger Craig; Jack Webb; Joe Cronin; Walter O'Malley' Mark Scott; Buzzi Bavasi; etc.; Non action -- side bar material. (Sleeve reads: SP-12696).; Caption slip reads: "Photographer: Jensen. Date: 1959-10-05. 42-43: Carl Furillo who is eager to play in spite of leg injuries as shown with bandages. 41: Bob Hunter interviews Roger Craig. 40: Jack Webb and Joe Cronin, President American League. 46: Walter O'Malley; Jack Webb; Mark Scott. 47: Buzzi Bavasi; Walter O'Malley talking champion".; Other caption slip reads: "Photographer: Miller. Date: 10-05. Reporter: Boejnoff. Assignment: Hats at game. 205: Mrs. Frances Diaz; Mrs. Eva Vega in Dodgers sailor hats. 224: Mrs. Zanie Amicone; Mrs. Marie Potratz, Dodgers hats with feather. 211: Mrs. Richard Albers and Mrs. Lee Ledbetter flashes dime store hat and no hat. 47: Mrs. Bertha Baker. 48: Mr. and Mrs. W.H. Slimer of Monrovia. 14: Mrs. Frank Oglesby; Mrs. Henry Brown in umbrella hat. 13: Miss Esther Place in fan's hat with radio. 206: Mrs. Tex Ritter with Mrs. and Mr. Tom Southworth. Ladies have hats from Honolulu".; Other caption slip reads: "Photographer: Olmo. Date: 1959-10-05. Assignment: Game sidebar. Daily. 11, 12: Close crowd showing white sheets. 13, 14, 16: Gilbert Sanchez, 10 interviews Walter o'Malley. 15: Gilbert Sanchez and Supervisor Warren Dorn".; Other caption slip reads: "Photographer: Olmo. Date: 1959-10-05. Assignment: Official scorers for sport. 10, left to right: Bob Hunter; Warren Brown; Les Biederman, the three official scorekeepers".
DOI: 10.15468/dl.hcum27
title: Occurrence Download

description: A dataset containing 89082 species occurrences available in GBIF matching the query:
{
 "and" : [
 "CoordinateUncertaintyInMeters 0.0-500.0",
 "OccurrenceStatus is Present",
 "TaxonKey is Trachemys scripta (Thunberg In Schoepff, 1792)"
 ]
}

 The dataset includes 89082 records from 290 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0015469-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25402/fon.17075384.v1
title: Supplementary Table 1. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer

description: Supplementary Table 1. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer <br>COX regression analysis of Gene mutation types and TKI drug types
DOI: 10.25402/fon.17085980
title: Supplementary Data: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

description: Supplementary Data. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisLiterature search criteria<br>
DOI: 10.25549/examiner-c44-51866
title: Dodgers parade, 1958

description: 24 images. Dodgers parade, 18 April 1958. Charles Dressen; Walt Alston; Carl Furillo (with monkey); Belle Valadez; Don Bessent; Don Drysdale; Mayor Norris Poulson; Norris Brandt (Poulson's grandson); Duke Snider; Walter O'Malley; Fog Horn Murphy.; Caption slip reads: "Photographer: Wilson. Date: 4-18. Assignment: Dodgers. 01: Carl Furillo with monkey. 00: Belle Valadez pinning LA sombrero on Dodgers at City Hall. Don Bessent (46). 66-67: L to R: Don Drysdale; Mayor Poulson with Norris Poulson Brandt, 3, grandson; Duke Snider with City Hall. 37-38: Parade past Hall of Records. 11: At 5th Street and Broadway, Mayor and grandson wave. 55-56: 6th Street and Broadway. 7: Chuck Dressen and Walt Alston waving at 6th Street -- 7th Street on Broadway. 8: At 7th Street. 64: Between 7th and 8th Streets. 60: On 7th Street with baloons. 61: Coliseum arrival. 33-34: Fog Horn Murphy at City Hall. 43-44: Dodgers players pass thru crowd on arrival at City Hall. 68-69: Long shots, City hall. 04: Home plate presentation, Poulson and O'Malley. 03: Group shot of Dodgers seated at City Hall. 22: Jack Felthouse presents California Flag to O'Malley".
DOI: 10.25402/fon.17085980.v1
title: Supplementary Data: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

description: Supplementary Data. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisLiterature search criteria<br>
DOI: 10.25402/fon.17085986
title: Supplementary Tables 1-5: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

description: Supplementary Table 1. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results of network meta-analysis. PlaCT= platinum-based chemotherapy. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.<br>Supplementary Table 2. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results in patients previously untreated, in patients receiving checkpoint inhibitors monotherapy or combination therapy subgroups. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. PlaCT= platinum-based chemotherapy. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.<br>Supplementary Table 3. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results in patients with advanced lung cancer receiving PD-1 inhibitors or PD-L1 inhibitors subgroup. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%. immunotherapy= immune checkpoint inhibitor; Prior+chem=previously treated with platinum-based chemotherapy.<br>Supplementary Table 4. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results for patients with PD-L1 TPS&lt;1%, TPS 1-49% and TPS≥50% subgroups. Platinum=platinum-based chemotherapy.<br>Supplementary Table 5. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisI2 values and Comparisons of the fit of consistency and inconsistency models using deviance information criteria (DIC).<br>
DOI: 10.25402/fon.17085986.v1
title: Supplementary Tables 1-5: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

description: Supplementary Table 1. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results of network meta-analysis. PlaCT= platinum-based chemotherapy. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.<br>Supplementary Table 2. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results in patients previously untreated, in patients receiving checkpoint inhibitors monotherapy or combination therapy subgroups. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. PlaCT= platinum-based chemotherapy. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.<br>Supplementary Table 3. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results in patients with advanced lung cancer receiving PD-1 inhibitors or PD-L1 inhibitors subgroup. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%. immunotherapy= immune checkpoint inhibitor; Prior+chem=previously treated with platinum-based chemotherapy.<br>Supplementary Table 4. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results for patients with PD-L1 TPS&lt;1%, TPS 1-49% and TPS≥50% subgroups. Platinum=platinum-based chemotherapy.<br>Supplementary Table 5. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisI2 values and Comparisons of the fit of consistency and inconsistency models using deviance information criteria (DIC).<br>
DOI: 10.25549/examiner-c44-82177
title: Pandas at Griffith Park Zoo, 1954

description: 11 images. Pandas at Griffith Park Zoo, 9 April 1954. A male and female panda from Orient.; Caption slip reads: "Photographer: Rustan. Date: 1954-04-09. Reporter: T. T. Assignment: Pandas at Griffith Park Zoo. Pix shows 2 pandas -- First ever displayed at local zoo. Value: $500 each -- Pandas, a male & a female, are young adults & unnamed at present -- Come from Orient".
DOI: 10.25402/fon.17104574
title: Supplementary Tables – Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study

description: Supplementary Table 1. Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study Distribution of answers in C19P-S.
DOI: 10.25402/fon.17104577
title: Supplementary Material – Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center studyw

description: Supplementary Material. Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study Survey to determine vaccine acceptance and hesitancy including COVID-19 phobia of cancer patients in response to the COVID-19 pandemic